NCT03938246Phase 2Completed

Study of TVB-2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH)

Study sponsor: Sagimet Biosciences Inc. · SGMT

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2021-10-02Actual

Enrollment · participants142Actual

Source updated2024-12-19Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)

Treatments or interventions studied

TVB-2640 25 mg (US)Drug
TVB-2640 50 mg (US)Drug
Placebo (US)Drug
TVB-2640 50 mg (China)Drug
Placebo (China)Drug
TVB-2640 75 mg (US)Drug

Primary outcomes · main study measures

measure: Percent Change in Hepatic Fat Fraction by Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) From Baseline; description: As determined by MRI-PDFF; timeFrame: 12 weeks

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history